{"id":12189,"date":"2025-06-10T01:17:00","date_gmt":"2025-06-10T01:17:00","guid":{"rendered":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/"},"modified":"2025-06-10T01:17:00","modified_gmt":"2025-06-10T01:17:00","slug":"%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5","status":"publish","type":"post","link":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/","title":{"rendered":"\u30102025 EHA\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9879\u8fdb\u5c55\u5165\u90092025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\u5e74\u4f1a"},"content":{"rendered":"<p><span class=\"legendSpanClass\">\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde<\/span><span class=\"legendSpanClass\">2025\u5e746\u670810\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001Bcl-2\u6291\u5236\u5242APG-2575\u3001EED\u6291\u5236\u5242APG-5918\u7b49\u91cd\u78c5\u54c1\u79cd\u768413\u9879\u7814\u7a76\u8fdb\u5c55\u5c06\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u4e8e\u610f\u5927\u5229\u7c73\u5170\u4e3e\u884c\u76842025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9879\u53e3\u5934\u62a5\u544a\uff0c\u53ca\u591a\u9879\u58c1\u62a5\u5c55\u793a\u548c\u7ebf\u4e0a\u53d1\u8868\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p>\n                        <a href=\"https:\/\/mma.prnewswire.com\/media\/2651720\/Ascentage_APAC_Logo.html\" target=\"_blank\" rel=\"noopener\"><\/a><\/p>\n<p>                        \n                <\/p>\n<\/div>\n<p>EHA\u5e74\u4f1a\u4f5c\u4e3a\u6b27\u6d32\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u4f1a\u8bae\uff0c\u6bcf\u5e74\u5438\u5f15\u6765\u81ea\u5168\u7403100\u591a\u4e2a\u56fd\u5bb6\u76841\u4e07\u591a\u540d\u4e13\u4e1a\u4eba\u58eb\u4e0e\u4f1a\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u8fdb\u5c55\u548c\u7a81\u7834\u6027\u4e34\u5e8a\u6570\u636e\u3002<\/p>\n<p>\u53e3\u5934\u62a5\u544a<\/p>\n<p>Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy<br \/>\u6574\u5408\u57fa\u56e0\u7ec4\u548c\u8f6c\u5f55\u7ec4\u5b66\u89c1\u89e3\u4ee5\u9884\u6d4b\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7597\u7684CML\u60a3\u8005\u7684\u7597\u6548\u548c\u7ed3\u5c40<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aS162\u5206\u4f1a\u573a\uff1aCML\u6cbb\u7597\u7597\u6548\u53ca\u8010\u836f\u7684\u751f\u7269\u5b66\uff08Biology of CML treatment response and resistance\uff09\u62a5\u544a\u65f6\u95f4\uff1a\u5317\u4eac\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b27\u6d32\u4e2d\u90e8\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09\u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u5f20\u5c0f\u5e05<\/p>\n<p>\u58c1\u62a5\u5c55\u793a<\/p>\n<p>Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study<br \/>\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u4e0e\u963f\u624e\u80de\u82f7\u7528\u4e8e\u65e0\u5316\u7597\u4e00\u7ebf\u6cbb\u7597\u65b0\u8bca\u65ad\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9879\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7ed3\u679c<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPF384\u5206\u4f1a\u573a\uff1a\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5 \u2013 \u4e34\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia &#8211; Clinical\uff09\u62a5\u544a\u65f6\u95f4\uff1a\u5317\u4eac\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b27\u6d32\u4e2d\u90e8\u65f6\u95f46\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09\u4e3b\u8981\u4f5c\u8005\uff1a\u82cf\u5dde\u5927\u5b66\u9644\u5c5e\u7b2c\u4e00\u533b\u9662\u5510\u6653\u6587\u6559\u6388\uff0c\u82cf\u5dde\u5927\u5b66\u9644\u5c5e\u7b2c\u4e00\u533b\u9662\u5f20\u6b23<\/p>\n<p>A Phase 2 Study of Olverembatinib for the Treatment of Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement<br \/>\u4e00\u9879\u8bc4\u4f30\u5965\u96f7\u5df4\u66ff\u5c3c\u7528\u4e8e\u6cbb\u7597\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u7cfb\u80bf\u7624\u7684II\u671f\u7814\u7a76<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPF390\u5206\u4f1a\u573a\uff1a\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5 \u2013 \u4e34\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia &#8211; Clinical\uff09\u62a5\u544a\u65f6\u95f4\uff1a\u5317\u4eac\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b27\u6d32\u4e2d\u90e8\u65f6\u95f46\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09\u4e3b\u8981\u4f5c\u8005\uff1a\u82cf\u5dde\u5927\u5b66\u9644\u5c5e\u7b2c\u4e00\u533b\u9662\u9648\u82cf\u5b81\u6559\u6388\uff0c\u82cf\u5dde\u5927\u5b66\u9644\u5c5e\u7b2c\u4e00\u533b\u9662\u8521\u6587\u6cbb<\/p>\n<p>Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia<br \/>\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408\u8d1d\u6797\u59a5\u6b27\u5355\u6297\u4e00\u7ebf\u6cbb\u7597\u8d39\u57ce\u67d3\u8272\u4f53\uff08Ph\uff09\u9633\u6027\u6216Ph\u6837\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7684\u7597\u6548\u548c\u5b89\u5168\u6027<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPS1367\u5206\u4f1a\u573a\uff1a\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5 \u2013 \u4e34\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia &#8211; Clinical\uff09\u62a5\u544a\u65f6\u95f4\uff1a\u5317\u4eac\u65f6\u95f46\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b27\u6d32\u4e2d\u90e8\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30 \uff09\u4e3b\u8981\u4f5c\u8005\uff1a\u5357\u65b9\u533b\u79d1\u5927\u5b66\u5357\u65b9\u533b\u9662\u5468\u7ea2\u5347\u6559\u6388\uff0c\u5357\u65b9\u533b\u79d1\u5927\u5b66\u5357\u65b9\u533b\u9662\u8bb8\u79c0\u4e3d<\/p>\n<p>Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial<br \/>\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408VP\u65b9\u6848\u4e00\u7ebf\u6cbb\u7597\u6210\u4eba\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9879\u5355\u81c2\u3001\u591a\u4e2d\u5fc3II\u671f\u7814\u7a76<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPS1372\u5206\u4f1a\u573a\uff1a\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5 \u2013 \u4e34\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia &#8211; Clinical\uff09\u62a5\u544a\u65f6\u95f4\uff1a\u5317\u4eac\u65f6\u95f46\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b27\u6d32\u4e2d\u90e8\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09\u4e3b\u8981\u4f5c\u8005\uff1a\u6d59\u6c5f\u5927\u5b66\u533b\u5b66\u9662\u9644\u5c5e\u7b2c\u4e00\u533b\u9662\u91d1\u6d01\u6559\u6388\uff0c\u6d59\u6c5f\u5927\u5b66\u533b\u5b66\u9662\u9644\u5c5e\u7b2c\u4e00\u533b\u9662\u8bb8\u6539\u9999<\/p>\n<p>Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study<br \/><span>\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408\u5965\u52a0\u4f0a\u59a5\u73e0\u5355\u6297\u6cbb\u7597\u590d\u53d1\u6216\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u524d\u6301\u7eedMRD\u9633\u6027\u6210\u4ebaPh+ ALL\u7684\u7597\u6548\u4e0e\u5b89\u5168\u6027\uff1a\u4e00\u9879\u2161\u671f\u7814\u7a76<\/span><\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPS1387\u5206\u4f1a\u573a\uff1a\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5 \u2013 \u4e34\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia &#8211; Clinical\uff09\u62a5\u544a\u65f6\u95f4\uff1a\u5317\u4eac\u65f6\u95f46\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b27\u6d32\u4e2d\u90e8\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09\u4e3b\u8981\u4f5c\u8005\uff1a\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u5317\u4eac\u534f\u548c\u533b\u5b66\u9662\u8840\u6db2\u75c5\u533b\u9662\u59dc\u5c14\u70c8\u6559\u6388\uff0c\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u5317\u4eac\u534f\u548c\u533b\u5b66\u9662\u8840\u6db2\u75c5\u533b\u9662\u5f20\u6f47\u4e88<\/p>\n<p>Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in Preclinical<br \/>T-Cell Lymphoma (TCL) Models<br \/>\u80da\u80ce\u5916\u80da\u5c42\u53d1\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5242APG-5918\u5728T\u7ec6\u80de\u6dcb\u5df4\u7624\uff08TCL\uff09\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u5c55\u73b0\u5f3a\u6548\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u5e76\u4e0e\u7ec4\u86cb\u767d\u53bb\u4e59\u9170\u5316\u9176\u6291\u5236\u5242\u897f\u8fbe\u672c\u80fa\u534f\u540c\u589e\u6548<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPS1993\u5206\u4f1a\u573a\uff1a\u6dcb\u5df4\u7624\u751f\u7269\u5b66\u4e0e\u8f6c\u5316\u7814\u7a76\uff08Lymphoma biology &amp; translational research\uff09\u62a5\u544a\u65f6\u95f4\uff1a\u5317\u4eac\u65f6\u95f46\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b27\u6d32\u4e2d\u90e8\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09\u4e3b\u8981\u4f5c\u8005\uff1a\u4e9a\u76db\u533b\u836fEric Liang\u535a\u58eb<\/p>\n<p>\u5728\u7ebf\u53d1\u5e03<\/p>\n<p>Alternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis<br \/>\u4f4e\u5242\u91cf\u5965\u52a0\u4f0a\u59a5\u73e0\u5355\u6297\u548c\u8d1d\u6797\u59a5\u6b27\u5355\u6297\u4ea4\u66ff\u7ef4\u6301\u6cbb\u7597\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08ALL\uff09\uff1a\u4e00\u9879\u5355\u4e2d\u5fc3\u56de\u987e\u6027\u5206\u6790<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPB2384\u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u533b\u79d1\u5927\u5b66\u7b2c\u4e8c\u533b\u9662\u8042\u5b50\u5143\u6559\u6388<\/p>\n<p>Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive\/Negative B-Cell Acute Lymphoblastic Leukemia<br \/>\u8d1d\u6797\u59a5\u6b27\u5355\u6297\u6cbb\u7597\u65b0\u786e\u8bca\u7684 Ph \u9633\u6027\/\u9634\u6027 B \u7ec6\u80de\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7597\u6548\u548c\u5b89\u5168\u6027<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPB2363\u4e3b\u8981\u4f5c\u8005\uff1a\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u534f\u548c\u533b\u9662\u5f20\u5bc5\u5af1<\/p>\n<p>Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients<br \/>\u7b2c\u4e09\u4ee3TKI\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u590d\u53d1\u548c\u6301\u7eedMRD\u9633\u6027\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7597\u6548\u4e0e\u5b89\u5168\u6027<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPB2360\u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u533b\u79d1\u5927\u5b66\u7b2c\u4e8c\u533b\u9662\u848b\u854a\u6e29<\/p>\n<p>Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study<br \/>\u4e34\u5e8a\u7279\u5f81\u548c\u57fa\u56e0\u5f02\u5e38\u7528\u4e8e\u9884\u6d4b\u63a5\u53d7\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u7684\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u6cbb\u7597\u7ed3\u5c40\uff1a\u4e00\u9879\u56de\u987e\u6027\u591a\u4e2d\u5fc3\u7814\u7a76<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPB2701\u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u539f\u68a6\u7476<\/p>\n<p>A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from <span class=\"xn-location\">China<\/span>: A Single-Center Retrospective Study<br \/>\u4e00\u9879\u8bc4\u4f30\u5965\u96f7\u5df4\u66ff\u5c3c\u7528\u4e8e\u6cbb\u7597\u4e2d\u56fd\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u771f\u5b9e\u4e16\u754c\u7814\u7a76\uff1a\u4e00\u9879\u5355\u4e2d\u5fc3\u56de\u987e\u6027\u7814\u7a76<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPB2714\u4e3b\u8981\u4f5c\u8005\uff1a\u56db\u5ddd\u5927\u5b66\u534e\u897f\u533b\u9662\u8463\u5929<\/p>\n<p>Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2\/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)<br \/>\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408Bcl-2\u6291\u5236\u5242lisaftoclax\uff08APG-2575\uff09\u548cBcl-2\/Bcl-xL\u6291\u5236\u5242pelcitoclax\uff08APG-1252\uff09\u5728T\u7ec6\u80de\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08T-ALL\uff09\u4e2d\u7684\u534f\u540c\u4f5c\u7528<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPB2341\u4e3b\u8981\u4f5c\u8005\uff1a\u4e9a\u76db\u533b\u836f\u5f6d\u6ce2<\/p>\n<p>\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7efc\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u7814\u53d1\u521b\u65b0\u836f\uff0c\u4ee5\u89e3\u51b3\u80bf\u7624\u7b49\u9886\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u56fd\u7eb3\u65af\u8fbe\u514b\u8bc1\u5238\u4ea4\u6613\u6240\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1aAAPG\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u5df2\u5efa\u7acb\u4e30\u5bcc\u7684\u521b\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\u3002<\/p>\n<p>\u516c\u53f8\u6838\u5fc3\u54c1\u79cd\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\uff0c\u4e14\u83b7\u6279\u9002\u5e94\u75c7\u5747\u88ab\u6210\u529f\u7eb3\u5165\u56fd\u5bb6\u533b\u4fdd\u836f\u54c1\u76ee\u5f55\uff0c\u76ee\u524d\uff0c\u4e9a\u76db\u533b\u836f\u6b63\u5728\u5f00\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9879\u83b7\u7f8e\u56fdFDA\u8bb8\u53ef\u7684\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u63a5\u53d7\u8fc7\u6cbb\u7597\u7684\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u8054\u5408\u6cbb\u7597\u65b0\u8bca\u65ad\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7597\u7425\u73c0\u9178\u8131\u6c22\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u80a0\u9053\u95f4\u8d28\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u6ce8\u518cIII\u671f\u7814\u7a76\u6b63\u5728\u5f00\u5c55\u4e2d\u3002<\/p>\n<p>\u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u79cd\uff0c\u65b0\u578bBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242APG-2575\uff08Lisaftoclax\uff09\u7684\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\uff08NDA\uff09\u5df2\u83b7CDE\u53d7\u7406\uff0c\u5e76\u88ab\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u3002\u76ee\u524d\uff0c\u4e9a\u76db\u533b\u836f\u6b63\u5728\u5f00\u5c55APG-2575\uff08Lisaftoclax\uff09\u56db\u9879\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\uff0c\u5206\u522b\u4e3a\u83b7\u7f8e\u56fdFDA\u8bb8\u53ef\u7684\u6cbb\u7597\u7ecf\u6cbb\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\uff08GLORA\uff09\uff1b\u6cbb\u7597\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\uff1b\u4e00\u7ebf\u6cbb\u7597\u65b0\u8bca\u65ad\u8001\u5e74\u6216\u4f53\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\uff1b\u4ee5\u53ca\u6cbb\u7597\u65b0\u8bca\u65ad\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684\u6ce8\u518cIII\u671f\u7814\u7a76\u3002<\/p>\n<p>\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u4e2a\u5728\u7814\u65b0\u836f\u5171\u83b716\u9879FDA\u548c1\u9879\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c2\u9879FDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u4ee5\u53ca2\u9879FDA\u513f\u7ae5\u7f55\u89c1\u75c5\u8d44\u683c\u8ba4\u8bc1\u3002\u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0e\u6b66\u7530\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f89\u745e\u3001\u4fe1\u8fbe\u7b49\u9886\u5148\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u56fd\u56fd\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b66\u7b49\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u5df2\u5728\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u9886\u57df\u5efa\u7acb\u7ecf\u9a8c\u4e30\u5bcc\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u4e0e\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c&#8221;\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42&#8221;\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n<p>\u524d\u77bb\u6027\u58f0\u660e<\/p>\n<p>\u672c\u65b0\u95fb\u7a3f\u5305\u542b\u6839\u636e\u7f8e\u56fd\u300a1995\u5e74\u79c1\u4eba\u8bc1\u5238\u8bc9\u8bbc\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7ecf\u4fee\u8ba2\u7684\u300a1933\u5e74\u8bc1\u5238\u6cd5\u300b\u7b2c27A\u6761\u548c\u300a1934\u5e74\u8bc1\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u6761\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9648\u8ff0\u3002\u9664\u5386\u53f2\u4e8b\u5b9e\u9648\u8ff0\u5916\uff0c\u672c\u65b0\u95fb\u7a3f\u4e2d\u7684\u6240\u6709\u5185\u5bb9\u5747\u53ef\u80fd\u6784\u6210\u524d\u77bb\u6027\u9648\u8ff0\uff0c\u5305\u62ec\u4e9a\u76db\u533b\u836f\u5bf9\u672a\u6765\u4e8b\u4ef6\u3001\u7ecf\u8425\u6210\u679c\u6216\u8d22\u52a1\u72b6\u51b5\u6240\u53d1\u8868\u7684\u610f\u89c1\u3001\u9884\u671f\u3001\u4fe1\u5ff5\u3001\u8ba1\u5212\u3001\u76ee\u6807\u3001\u5047\u8bbe\u6216\u9884\u6d4b\u3002<\/p>\n<p>\u8fd9\u4e9b\u524d\u77bb\u6027\u9648\u8ff0\u53d7\u5230\u8bf8\u591a\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u7684\u5f71\u54cd\uff0c\u5177\u4f53\u5185\u5bb9\u5df2\u5728\u4e9a\u76db\u533b\u836f\u5411\u7f8e\u56fd\u8bc1\u5238\u4ea4\u6613\u59d4\u5458\u4f1a\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8be6\u7ec6\u8bf4\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7ecf\u4fee\u8ba2\u7684F-1\u8868\u683c\u6ce8\u518c\u8bf4\u660e\u4e66\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684&#8221;\u98ce\u9669\u56e0\u7d20&#8221;\u548c&#8221;\u5173\u4e8e\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u884c\u4e1a\u6570\u636e\u7684\u7279\u522b\u8bf4\u660e&#8221;\u7ae0\u8282\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u53d1\u884c\u4e0a\u5e02\u62db\u80a1\u4e66\u4e2d\u7684&#8221;\u524d\u77bb\u6027\u58f0\u660e&#8221;\u3001&#8221;\u98ce\u9669\u56e0\u7d20&#8221;\u7ae0\u8282\uff0c\u4ee5\u53ca\u6211\u4eec\u4e0d\u65f6\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u8fd9\u4e9b\u56e0\u7d20\u53ef\u80fd\u5bfc\u81f4\u5b9e\u9645\u4e1a\u7ee9\u3001\u8fd0\u8425\u6c34\u5e73\u3001\u7ecf\u8425\u6210\u679c\u6216\u6210\u5c31\u4e0e\u524d\u77bb\u6027\u9648\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u5f02\u3002\u672c\u524d\u77bb\u6027\u58f0\u660e\u4e2d\u7684\u9648\u8ff0\u4e0d\u6784\u6210\u516c\u53f8\u7ba1\u7406\u5c42\u7684\u5229\u6da6\u9884\u6d4b\u3002<\/p>\n<p>\u56e0\u6b64\uff0c\u8be5\u7b49\u524d\u77bb\u6027\u9648\u8ff0\u4e0d\u5e94\u88ab\u89c6\u4e3a\u5bf9\u672a\u6765\u4e8b\u4ef6\u7684\u9884\u6d4b\u3002\u672c\u65b0\u95fb\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u57fa\u4e8e\u4e9a\u76db\u533b\u836f\u5f53\u524d\u5bf9\u672a\u6765\u53d1\u5c55\u53ca\u5176\u6f5c\u5728\u5f71\u54cd\u7684\u9884\u671f\u548c\u5224\u65ad\uff0c\u4e14\u4ec5\u4ee3\u8868\u622a\u81f3\u9648\u8ff0\u53d1\u8868\u4e4b\u65e5\u7684\u89c2\u70b9\u3002\u65e0\u8bba\u51fa\u73b0\u65b0\u4fe1\u606f\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u4e9a\u76db\u533b\u836f\u5747\u65e0\u4e49\u52a1\u66f4\u65b0\u6216\u4fee\u8ba2\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u3002<\/p>\n<p>SOURCE  \u4e9a\u76db\u533b\u836f<\/p>","protected":false},"excerpt":{"rendered":"<p>\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2025\u5e746\u670810\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001Bcl-2\u6291\u5236\u5242APG-2575\u3001EED\u6291\u5236\u5242APG-5918\u7b49\u91cd\u78c5\u54c1\u79cd\u768413\u9879\u7814\u7a76\u8fdb\u5c55\u5c06\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u4e8e\u610f\u5927\u5229\u7c73\u5170\u4e3e\u884c\u76842025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9879\u53e3\u5934\u62a5\u544a\uff0c\u53ca\u591a\u9879\u58c1\u62a5\u5c55\u793a\u548c\u7ebf\u4e0a\u53d1\u8868\u3002 EHA\u5e74\u4f1a\u4f5c\u4e3a\u6b27\u6d32\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u4f1a\u8bae\uff0c\u6bcf\u5e74\u5438\u5f15\u6765\u81ea\u5168\u7403100\u591a\u4e2a\u56fd\u5bb6\u76841\u4e07\u591a\u540d\u4e13\u4e1a\u4eba\u58eb\u4e0e\u4f1a\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u8fdb\u5c55\u548c\u7a81\u7834\u6027\u4e34\u5e8a\u6570\u636e\u3002 \u53e3\u5934\u62a5\u544a Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy\u6574\u5408\u57fa\u56e0\u7ec4\u548c\u8f6c\u5f55\u7ec4\u5b66\u89c1\u89e3\u4ee5\u9884\u6d4b\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7597\u7684CML\u60a3\u8005\u7684\u7597\u6548\u548c\u7ed3\u5c40 \u6458\u8981\u7f16\u53f7\uff1aS162\u5206\u4f1a\u573a\uff1aCML\u6cbb\u7597\u7597\u6548\u53ca\u8010\u836f\u7684\u751f\u7269\u5b66\uff08Biology of CML treatment response and resistance\uff09\u62a5\u544a\u65f6\u95f4\uff1a\u5317\u4eac\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b27\u6d32\u4e2d\u90e8\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09\u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u5f20\u5c0f\u5e05 \u58c1\u62a5\u5c55\u793a Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u4e0e\u963f\u624e\u80de\u82f7\u7528\u4e8e\u65e0\u5316\u7597\u4e00\u7ebf\u6cbb\u7597\u65b0\u8bca\u65ad\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9879\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7ed3\u679c \u6458\u8981\u7f16\u53f7\uff1aPF384\u5206\u4f1a\u573a\uff1a\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5 [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":12190,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-12189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u30102025 EHA\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9879\u8fdb\u5c55\u5165\u90092025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\u5e74\u4f1a - Money Compass CN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/moneycompass.com.my\/cn\/\u30102025-eha\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u548capg-2575\u7b4913\u9879\u8fdb\u5c55\u5165\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u30102025 EHA\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9879\u8fdb\u5c55\u5165\u90092025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\u5e74\u4f1a - Money Compass CN\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2025\u5e746\u670810\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001Bcl-2\u6291\u5236\u5242APG-2575\u3001EED\u6291\u5236\u5242APG-5918\u7b49\u91cd\u78c5\u54c1\u79cd\u768413\u9879\u7814\u7a76\u8fdb\u5c55\u5c06\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u4e8e\u610f\u5927\u5229\u7c73\u5170\u4e3e\u884c\u76842025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9879\u53e3\u5934\u62a5\u544a\uff0c\u53ca\u591a\u9879\u58c1\u62a5\u5c55\u793a\u548c\u7ebf\u4e0a\u53d1\u8868\u3002 EHA\u5e74\u4f1a\u4f5c\u4e3a\u6b27\u6d32\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u4f1a\u8bae\uff0c\u6bcf\u5e74\u5438\u5f15\u6765\u81ea\u5168\u7403100\u591a\u4e2a\u56fd\u5bb6\u76841\u4e07\u591a\u540d\u4e13\u4e1a\u4eba\u58eb\u4e0e\u4f1a\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u8fdb\u5c55\u548c\u7a81\u7834\u6027\u4e34\u5e8a\u6570\u636e\u3002 \u53e3\u5934\u62a5\u544a Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy\u6574\u5408\u57fa\u56e0\u7ec4\u548c\u8f6c\u5f55\u7ec4\u5b66\u89c1\u89e3\u4ee5\u9884\u6d4b\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7597\u7684CML\u60a3\u8005\u7684\u7597\u6548\u548c\u7ed3\u5c40 \u6458\u8981\u7f16\u53f7\uff1aS162\u5206\u4f1a\u573a\uff1aCML\u6cbb\u7597\u7597\u6548\u53ca\u8010\u836f\u7684\u751f\u7269\u5b66\uff08Biology of CML treatment response and resistance\uff09\u62a5\u544a\u65f6\u95f4\uff1a\u5317\u4eac\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b27\u6d32\u4e2d\u90e8\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09\u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u5f20\u5c0f\u5e05 \u58c1\u62a5\u5c55\u793a Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u4e0e\u963f\u624e\u80de\u82f7\u7528\u4e8e\u65e0\u5316\u7597\u4e00\u7ebf\u6cbb\u7597\u65b0\u8bca\u65ad\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9879\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7ed3\u679c \u6458\u8981\u7f16\u53f7\uff1aPF384\u5206\u4f1a\u573a\uff1a\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/moneycompass.com.my\/cn\/\u30102025-eha\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u548capg-2575\u7b4913\u9879\u8fdb\u5c55\u5165\/\" \/>\n<meta property=\"og:site_name\" content=\"Money Compass CN\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T01:17:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/06\/Ascentage_APAC_Logo-KpvIvA.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"144\" \/>\n\t<meta property=\"og:image:height\" content=\"54\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/\",\"name\":\"\u30102025 EHA\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9879\u8fdb\u5c55\u5165\u90092025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\u5e74\u4f1a - Money Compass CN\",\"isPartOf\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/06\/Ascentage_APAC_Logo-KpvIvA.jpeg\",\"datePublished\":\"2025-06-10T01:17:00+00:00\",\"dateModified\":\"2025-06-10T01:17:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/#primaryimage\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/06\/Ascentage_APAC_Logo-KpvIvA.jpeg\",\"contentUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/06\/Ascentage_APAC_Logo-KpvIvA.jpeg\",\"width\":144,\"height\":54},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/moneycompass.com.my\/cn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u30102025 EHA\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9879\u8fdb\u5c55\u5165\u90092025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\u5e74\u4f1a\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/\",\"name\":\"Money Compass CN\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30102025 EHA\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9879\u8fdb\u5c55\u5165\u90092025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\u5e74\u4f1a - Money Compass CN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/moneycompass.com.my\/cn\/\u30102025-eha\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u548capg-2575\u7b4913\u9879\u8fdb\u5c55\u5165\/","og_locale":"en_US","og_type":"article","og_title":"\u30102025 EHA\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9879\u8fdb\u5c55\u5165\u90092025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\u5e74\u4f1a - Money Compass CN","og_description":"\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2025\u5e746\u670810\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001Bcl-2\u6291\u5236\u5242APG-2575\u3001EED\u6291\u5236\u5242APG-5918\u7b49\u91cd\u78c5\u54c1\u79cd\u768413\u9879\u7814\u7a76\u8fdb\u5c55\u5c06\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u4e8e\u610f\u5927\u5229\u7c73\u5170\u4e3e\u884c\u76842025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9879\u53e3\u5934\u62a5\u544a\uff0c\u53ca\u591a\u9879\u58c1\u62a5\u5c55\u793a\u548c\u7ebf\u4e0a\u53d1\u8868\u3002 EHA\u5e74\u4f1a\u4f5c\u4e3a\u6b27\u6d32\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u4f1a\u8bae\uff0c\u6bcf\u5e74\u5438\u5f15\u6765\u81ea\u5168\u7403100\u591a\u4e2a\u56fd\u5bb6\u76841\u4e07\u591a\u540d\u4e13\u4e1a\u4eba\u58eb\u4e0e\u4f1a\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u8fdb\u5c55\u548c\u7a81\u7834\u6027\u4e34\u5e8a\u6570\u636e\u3002 \u53e3\u5934\u62a5\u544a Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy\u6574\u5408\u57fa\u56e0\u7ec4\u548c\u8f6c\u5f55\u7ec4\u5b66\u89c1\u89e3\u4ee5\u9884\u6d4b\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7597\u7684CML\u60a3\u8005\u7684\u7597\u6548\u548c\u7ed3\u5c40 \u6458\u8981\u7f16\u53f7\uff1aS162\u5206\u4f1a\u573a\uff1aCML\u6cbb\u7597\u7597\u6548\u53ca\u8010\u836f\u7684\u751f\u7269\u5b66\uff08Biology of CML treatment response and resistance\uff09\u62a5\u544a\u65f6\u95f4\uff1a\u5317\u4eac\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b27\u6d32\u4e2d\u90e8\u65f6\u95f46\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09\u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u5f20\u5c0f\u5e05 \u58c1\u62a5\u5c55\u793a Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u4e0e\u963f\u624e\u80de\u82f7\u7528\u4e8e\u65e0\u5316\u7597\u4e00\u7ebf\u6cbb\u7597\u65b0\u8bca\u65ad\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9879\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7ed3\u679c \u6458\u8981\u7f16\u53f7\uff1aPF384\u5206\u4f1a\u573a\uff1a\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5 [&hellip;]","og_url":"https:\/\/moneycompass.com.my\/cn\/\u30102025-eha\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u548capg-2575\u7b4913\u9879\u8fdb\u5c55\u5165\/","og_site_name":"Money Compass CN","article_published_time":"2025-06-10T01:17:00+00:00","og_image":[{"width":144,"height":54,"url":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/06\/Ascentage_APAC_Logo-KpvIvA.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/","url":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/","name":"\u30102025 EHA\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9879\u8fdb\u5c55\u5165\u90092025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\u5e74\u4f1a - Money Compass CN","isPartOf":{"@id":"https:\/\/moneycompass.com.my\/cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/#primaryimage"},"image":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/#primaryimage"},"thumbnailUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/06\/Ascentage_APAC_Logo-KpvIvA.jpeg","datePublished":"2025-06-10T01:17:00+00:00","dateModified":"2025-06-10T01:17:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/#primaryimage","url":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/06\/Ascentage_APAC_Logo-KpvIvA.jpeg","contentUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/06\/Ascentage_APAC_Logo-KpvIvA.jpeg","width":144,"height":54},{"@type":"BreadcrumbList","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902025-eha%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e6%a0%b8%e5%bf%83%e4%ba%a7%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a1%b9%e8%bf%9b%e5%b1%95%e5%85%a5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/moneycompass.com.my\/cn\/"},{"@type":"ListItem","position":2,"name":"\u30102025 EHA\u3011\u4e9a\u76db\u533b\u836f\u6838\u5fc3\u4ea7\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9879\u8fdb\u5c55\u5165\u90092025\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\u5e74\u4f1a"}]},{"@type":"WebSite","@id":"https:\/\/moneycompass.com.my\/cn\/#website","url":"https:\/\/moneycompass.com.my\/cn\/","name":"Money Compass CN","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/12189"}],"collection":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/comments?post=12189"}],"version-history":[{"count":0,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/12189\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media\/12190"}],"wp:attachment":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media?parent=12189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/categories?post=12189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/tags?post=12189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}